Pr Christophe Massard

Spécialité

Oncologue médical, expert vessie, expert prostate

Titre

Chef du Département des Essais Précoces (DITEP)

Hôpital

Gustave Roussy (Villejuif)

Derniers articles

• Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry. (1 avr. 2025)
• Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. (17 mars 2025)
• Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. (10 mars 2025)
• AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: Phase I trial in Patients with Advanced Solid Tumors. (12 févr. 2025)
• Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting. (1 févr. 2025)